Literature DB >> 17229005

Update on the epidemiology of Paget's disease of bone.

Cyrus Cooper1, Nicholas C Harvey, Elaine M Dennison, Tjeerd P van Staa.   

Abstract

Paget's disease of bone (PDB) is characterized by rapid bone remodeling and the formation of bone that is structurally abnormal. Recent studies have confirmed that both genetic and environmental factors are important in its etiology. Epidemiological studies in Europe and North America have revealed that PDB shows an increasing frequency of occurrence with age and is more prevalent among men than women. There is marked geographic variation in the prevalence of PDB throughout western nations, with the highest rates reported during the 1970s in Britain. Recent studies of the secular trends in PDB suggest declining rates in both prevalence and severity at diagnosis. Thus, the overall age/sex standardized prevalence rate in Britain during the period 1993-1995 was found to be 2.5% among men and 1.6% among women > or = 55 years of age. Prevalence rates had fallen by approximately 50% in several of the centers studied, suggesting an environmental contribution to the etiology of this disorder. Similar findings have been reported from other European countries and New Zealand. Recent study of the incidence and clinical manifestations of PDB have emerged from large cohort studies in primary care record linkage resources, such as the General Practice Research Database. Over the period 1988-1999, the incidence rate of clinically diagnosed PDB was found to be 5 per 10,000 person-years among men and 3 per 10,000 person-years among women 75 years of age. The disorder was associated with an increased risk of back pain (RR, 2.1; 95% CI, 1.9-2.3); osteoarthritis (RR, 1.7; 95% CI, 1.5-1.9); and fracture (RR, 1.2; 95% CI, 1.0-1.5). Using life table methodology, the estimated proportion of patients dying within 5 years of follow-up was 32.7% among the cohort with PDB compared with 28.0% among control patients (p < 0.05).

Entities:  

Mesh:

Year:  2006        PMID: 17229005     DOI: 10.1359/jbmr.06s201

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  27 in total

1.  Five-year follow-up of Japanese patients with Paget's disease of the bone after treatment with low-dose oral alendronate: a case series.

Authors:  Kousuke Iba; Junichi Takada; Takuro Wada; Toshihiko Yamashita
Journal:  J Med Case Rep       Date:  2010-05-31

2.  Efficacy, tolerability, and safety of risedronate in Japanese patients with Paget's disease of bone.

Authors:  Kousei Yoh; Shinjiro Takata; Noriko Yoshimura; Jun Hashimoto
Journal:  J Bone Miner Metab       Date:  2010-02-24       Impact factor: 2.626

Review 3.  Founders lecture 2007: Metabolic bone disease: what has changed in 30 years?

Authors:  Murali Sundaram
Journal:  Skeletal Radiol       Date:  2009-03-05       Impact factor: 2.199

4.  Nonlinear association between bone mineral density and all-cause mortality: the Dong-gu study.

Authors:  C K Choi; S -S Kweon; Y -H Lee; H -S Nam; K -S Park; S -Y Ryu; S -W Choi; S A Kim; M -H Shin
Journal:  Osteoporos Int       Date:  2018-07-16       Impact factor: 4.507

5.  Paget's Disease of Bone: A Review of Epidemiology, Pathophysiology and Management.

Authors:  Joseph L Shaker
Journal:  Ther Adv Musculoskelet Dis       Date:  2009-04       Impact factor: 5.346

Review 6.  [Pathological and metabolic bone diseases: Clinical importance for fracture treatment].

Authors:  R Oheim
Journal:  Unfallchirurg       Date:  2015-12       Impact factor: 1.000

7.  Epidemiology of Paget's disease of bone in the city of Recife, Brazil.

Authors:  Rainier Luz Reis; Maíra Falcão Poncell; Erik Trovão Diniz; Francisco Bandeira
Journal:  Rheumatol Int       Date:  2011-09-14       Impact factor: 2.631

8.  Decreasing severity of Paget's disease of bone in northern Italy over the last two decades: results of a monocentric study on 391 patients.

Authors:  M Varenna; F Zucchi; C Crotti; M Manara; R Caporali
Journal:  Osteoporos Int       Date:  2021-02-22       Impact factor: 4.507

9.  Symptomatic intracranial hypertension and prolonged hypocalcemia following treatment of Paget's disease of the skull with zoledronic acid.

Authors:  Bruno Ferraz-de-Souza; Regina M Martin; Pedro Henrique S Correa
Journal:  J Bone Miner Metab       Date:  2012-10-18       Impact factor: 2.626

10.  A SQSTM1/p62 mutation linked to Paget's disease increases the osteoclastogenic potential of the bone microenvironment.

Authors:  Yuko Hiruma; Noriyoshi Kurihara; Mark A Subler; Hua Zhou; Christina S Boykin; Heju Zhang; Seiichi Ishizuka; David W Dempster; G David Roodman; Jolene J Windle
Journal:  Hum Mol Genet       Date:  2008-09-02       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.